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Introduction: Myoclonus may be a rare complication of stem cell transplant but has limited discussion in the
scientiﬁc literature.
Case:Wepresent a case of an acutemyeloid leukemia survivorwho developed refractorymyoclonic epilepsy four
years after graft versus host disease (GVHD) developed six days following matched unrelated allogeneic
hematopoietic stem cell transplant.
Discussion: Graft versus host disease occurs in 30–50% of allogenic hematopoietic stem cell transplant patients
and may cause pharmacoresistant myoclonic epilepsy; however, the mechanisms by which GVHD leads to
recurrent myoclonic seizures are not well understood (Lee, 2005) [1]. The paucity of clinical reports of such
manifestation makes it difﬁcult to diagnose and effectively manage these patients.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The deﬁnition of “epileptic myoclonus” has changed several times
over the past 3 decades.Myoclonus is currently deﬁned as sudden invol-
untary jerking of a muscle or groups [2]. Myoclonus is associated with
multiple epilepsy syndromes such as juvenile myoclonic epilepsy and
the progressive myoclonic epilepsies. Although the neurophysiology of
myoclonus is incompletely understood [1], spatial and temporal ampli-
ﬁcation within relevant networks may cause the epileptic motor
activity. [3].
Recently, graft versus host disease was observed to cause central
nervous system (CNS) complications following allogenic stem cell
transplants (allo-HSCTs) [4–9]. However, very few patients have
presented with myoclonus [6,9]. We describe an allo-HSCT patient
who developed chronic GVHD, associated with intractable myoclonic
seizures. This appears to be an uncommon example of symptomatic
myoclonic epilepsy, deﬁned as clinical myoclonus associated with
diffuse polyspike activity on EEG following a known cerebral insult., Penn State Hershey College of
. This is an open access article under2. Case
A 48-year-old male was diagnosed with Philadelphia chromosome
positive acute myelogenous leukemia in 9/03/2008. He received a
7 + 3 induction chemotherapy (3 days of daunorubicin and 7 days of
continuous infusion of cytosine arabinoside) in September with
400 mg of imatinib given for 14 days of the induction. A bone marrow
on 10/23/2008 was consistent with a complete remission — there was
no morphological evidence of residual acute leukemia. At that time,
quantitative PCR for bcr-abl p210, previously positive, was negative.
Imatinib was resumed at 800 mg daily. The patient subsequently
remained in complete morphological and molecular remission of
his leukemia. He then received nonmyeloablative conditioning
chemotherapy with ﬂudarabine and cyclophosphamide prior to
allogenic stem cell transplantation with matched unrelated donor stem
cells on 2/23/09 without incident. He remained stable and tolerated
the course well.
The patient recovered normal hematopoiesis rapidly, but donor
engraftment as documented by XY ﬂuorescence in-situ hybridization
(FISH) was initially modest — XX was initially only 1.4%.
Between 06/22/2009 and 07/23/2009, his XX engraftment rose from
9.2% to 98.0%. He was diagnosed with chronic graft versus host disease
on 10/20/2011 (more than two years after stem cell transplant); the
patient presented with signiﬁcant irritation and thickening of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.MRI of axial FLAIR sequence with right periventricular increased signal.
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topical oral dexamethasone swish and spit and tacrolimus.
In June 2012, the patient presented with myoclonic jerks involving
his arms and legs. They caused occasional falls, but he denied any loss
of consciousness. In spite of levetiracetam, he continued to have epi-
sodes multiple times per day. Hewas admitted to the neurology service
after a myoclonic jerk that resulted in a fall with loss of consciousness.
His neurological examwasunremarkable except for frequentmyoclonic
jerks of the extremities with brief alteration in awareness and respon-
siveness. Brain magnetic resonance imaging revealed periventricularFig. 2. EEG with diffuse polyspike activity associated with prominentwhite matter lesions (Fig. 1). Electroencephalography showed frequent
generalized 40–70 uV polyspike activity that occurred in runs lasting
from 0.5–3 s, maximal in the frontocentral regions (Fig. 2). This activity
was seen spontaneously and during photic stimulation. Perampanel im-
proved his symptoms by 40%. However, his seizures thenworsened and
were intractable to levetiracetam, valproic acid, topiramate, lorazepam,
clonazepam, zonisamide, and lacosamide. Vagal nerve stimulation did
not improve the frequency or severity of the myoclonic jerks. For chro-
nic oral graft versus host disease, the patient requires ongoing
immunosuppression with tacrolimus, mycophenolate, and oral topical
dexamethasone. Attempts to taper tacrolimus have resulted in prob-
lematic ulcerative oral inﬂammation. In spite of immunosuppressive
agents, he experiences some ongoing oral mucosal irritation.3. Discussion
Chronic GVHD is recognized to cause neurological manifestations
[4–9], but little is known about its relationship with symptomatic
myoclonus, resulting in a scarcity of information of the natural history
or treatment outcomes. Initially, our patient received partial relief from
perampanel, but his condition proved to be intractable to more than
eight antiepileptic drugs and vagal nerve stimulation. He continues to
have 3 or more seizures per hour, resulting in up to 100 per day. We
summarize several case studies written within the last 30 years in
Table 1. However, nearly all reported patients have died or are still suf-
fering from severe epilepsy. Further research is needed to determine an
appropriate protocol for patients who develop myoclonus following
GVHD.Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.myoclonus consisting of brief ﬂexion of the neck and both legs.
Table 1
Author Type of
transplant/GVHD
Number
of
patients
Clinical features MRI/neuropathology CSF EEG Other Type of
seizures
Treatment for
epilepsy
Treatment
outcome
Time of onset
after transplant
Starzl
et al.
(1978)
[10]
OLT 9 Leg spasticity, decreased
mentation, right
hemiparesis, akinetic
mutism, stupor and
coma, seizures
Multifocal areas of
infarction
in cerebral cortex and
basal ganglia, CPM
N/A Diffusely slow and
nonfocal
Cerebral angiography:
thrombotic or embolic
disease
G, F N/A Died Between 3 and 72
days
Adams
et al.
(1987)
[11]
OLT 13 Convulsions N/A N/A Focal EEG
abnormalities, right
posterior quadrant
abnormalities, right
sided continuous
spikes
CAT scan showing low
density areas right
occipital lobe
G (10),
F (1), M
(2)
Phenytoin
(worked in 10
of 13)
Died in SE (2) Median: 7 days
Iwasaki
et al.
(1993)
[8]
allo-HSCT 2 Encephalopathy,
spasticity, seizures
Cortical atrophy,
ventricular
dilatation
EP, Pleo N/A Autopsy: diffuse
inﬁltration
of white matter with
CD3 lymphocytes
G N/A Died Both patients died
8–9 months after
transplant.
Provenzale
and
Graham
(1996)
[6]
allo-HSCT 1 Disorientation,
myoclonus, tremor
Diffuse WML, multiple
foci of
hyper-intense signal on
T2-weighted images in
the brain stem and deep
white matter
EP, elevated
IGG and
albumin, no
Pleo
Diffuse slowing Biopsy of colonic
mucosa: persistent
GVHD
M Methyl
prednisone
Partial
response
died on day
123
71 days
Ma et al.
(2002)
[12]
allo-HSC 1 Cognitive decline,
seizures, encephalopathy
WML, atrophy EP + L, NG Moderate to severe
bilateral slowing
Antemortem histology:
vasculitis
F Methyl
prednisone
Partial
improvement
2 months
Shortt
et al.
(2006)
[13]
auto-HSCT and
allo-HSCT
1 Personality changes,
seizures, cognitive
dysfunction, headache
Diffuse WML with
periventricular
predominance
EP + L, NG N/A No brain biopsy F Methyl
prednisolone,
phenytoin, and
sirolimus
Complete
response
14 months after
second transplant
Kamble
et al.
(2007)
[5]
allo-HSCT/ 2 Right
hemiparesis/encephalopathy,
seizures
Inﬁltrating WML, left
frontal parietal lobe
with minimal
enhancement/patch
areas of increased
intensity in
pontine white matter,
caudate nuclei,
putamina, bilateral
cerebral and
cerebellar white matter
WNL/EP+ L,
NG, normal
LDH
N/A Perivascular
lymphocytic inﬁltrates
composed of
T-lymphocytes from the
donor predominantly in
the brain parenchyma
(BB), autopsy:
leptomeningeal
perivascular
inﬂammation
N/A Methyl
prednisone/high
dose steroids
Complete
response,
died
18 months/178 days
Zhang
et al.
(2013)
[14]
allo-HSCT 79 Seizures Demyelination (8), CNS
infection
(8), intracranial
hemorrhage (3),
cerebral infarction (2),
and CNS tumors (1)
WNL (3),
increased
pressure or
EP (12)
Abnormal (2) CNS fungal infection
(BB, 1)
F (21),
G (51)
Diazepam and
phenobarbital
42 (53.2%)
died
Conditioning stage
(3), day 0–100 (52),
day 100–365 (20),
365+ (4)
Abbreviations: F= focal, G= generalized, M=myoclonus, N/A= not available, OLT= orthotropic liver transplant, allo-HSCT= allogeneic hematopoietic stem cell transplant, auto-HSCT= autogenic hematopoietic stem transplant,WML=white
matter lesion, CPM= central pontinemyelinolysis, EP= elevated protein, EP+ L= elevated protein+ lymphocytes, NG=normal glucose, LDH= lactate dehydrogenase, Pleo= Pleocytosis, CSF= cerebral spinal ﬂuid, MRI=magnetic resonance
imaging, CAT = computer axial tomography, GVHD= graft versus host disease, WNL = within normal limits, BB = brain biopsy.
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